Kaveh Zakeri, MD, MAS | Authors

Kaveh Zakeri, MD, MAS, is a radiation oncologist in the Department of Radiation Oncology at Memorial Sloan Kettering Cancer Center. Zakeri specializes in head and neck cancers, skin cancer, lung caners, palliative care, and metastatic disease.


JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCC

June 26, 2021

The potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.

Further Research Needed to Support Use of Checkpoint Inhibitors in Locally Advanced HNSCC

May 06, 2021

Avelumab was explored in a clinical trial for the treatment of locally advanced head and neck squamous cell carcinoma, but more research is needed to position the agent and other checkpoint inhibitors in the treatment landscape, experts say.